Tag: ASCO
OSE Immunotherapeutics Presents Clinical Abstracts on Tedopi® at the ASCO 2023...
Tedopi® is the Company's Most Advanced Product in Clinical Development
ATALANTE-1, a Phase 3 clinical trial with positive results comparing Tedopi® to chemotherapy in...
Live from ASCO 2023 | Ascentage Pharma Releases Updated Data Showing...
SUZHOU, China and ROCKVILLE, Md., June 6, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer,...
Gencurix Announces Clinical Research Results At ASCO 2023 Demonstrating Outstand… –...
SEOUL, South Korea, June 4, 2023 /PRNewswire/ -- Gencurix (KOSDAQ #229000), a leading provider of cancer molecular diagnostics, announced the release of clinical...
Genomic Testing Cooperative Presents at ASCO meeting Studies Demonstrating the P…...
Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting three...
ASCO 2023: Integra Connect to Showcase how its Technology and Real-World...
Research includes 12 posters and abstracts, including studies with Thermo Fisher ScientificWEST PALM BEACH, Fla., May 26, 2023 /PRNewswire/ -- Integra Connect, LLC., the...
New Data to be Shared at ASCO 2022 Underscore Clinical Utility...
- First findings from study analyzing outcomes of more than 10,000 men in national SEER database who underwent Decipher testing -
Veracyte, Inc. VCYT...
ASCO 2022 | Ascentage Pharma to Present Data from Seven Clinical...
SUZHOU, China, and ROCKVILLE, MD, April 27, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers,...
Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in Advanced...
Median Duration of Response (DOR) Not Reached at 33.1 Months of Median Study Follow Up in Cohort 2 in C-144-01 Study ...
Coherus and Junshi Biosciences to Host Virtual Investor Event to Discuss...
SHANGHAI, China, and REDWOOD CITY, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE:...
Sorrento Announces Positive Results From Its License Partner, Kelun, on a...
A166 (ASCO Abstract #1024) is a third generation antibody drug conjugate (ADC) against HER2-positive breast cancer with Levena’s proprietary tubulin inhibitor Duo-5 toxin,...